Your browser doesn't support javascript.
Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.
Surtees, Rebecca; Stern, Daniel; Ahrens, Katharina; Kromarek, Nicole; Lander, Angelika; Kreher, Petra; Weiss, Sabrina; Hewson, Roger; Punch, Emma K; Barr, John N; Witkowski, Peter T; Couacy-Hymann, Emmanuel; Marzi, Andrea; Dorner, Brigitte G; Kurth, Andreas.
  • Surtees R; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Stern D; Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Ahrens K; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Kromarek N; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Lander A; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Kreher P; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Weiss S; Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
  • Hewson R; Virology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, United Kingdom.
  • Punch EK; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom.
  • Barr JN; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom.
  • Witkowski PT; Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.
  • Couacy-Hymann E; Laboratoire National d'Appui au Développement Agricole, Bingerville, Ivory Coast.
  • Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States of America.
  • Dorner BG; Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
  • Kurth A; Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
PLoS Negl Trop Dis ; 14(10): e0008699, 2020 10.
Article in English | MEDLINE | ID: covidwho-932350
ABSTRACT
Surveillance of highly pathogenic viruses circulating in both human and animal populations is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the burden of disease by serological assay could be used as an early warning system for imminent outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the multitude of highly pathogenic viruses necessitates the need to identify specific antibodies against several targets from both humans as well as from potential reservoir animals such as bats. In order to address this, we have developed a broadly reactive multiplex microsphere immunoassay (MMIA) for the detection of antibodies against several highly pathogenic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each respective NP was shown by testing sera from humans and non-human primates with known infection status. The usefulness of our assay for serosurveillance was shown by determining the immune response against the NP antigens in a panel of 129 human serum samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera from the German blood bank. We found good agreement between our MMIA and commercial or in-house reference methods by ELISA or IIFT with statistically significant higher binding to both EBOV NP and MARV NP coupled microspheres in the Guinea panel. Finally, the MMIA was successfully adapted to detect antibodies from bats that had been inoculated with EBOV- and MARV- virus-like particles, highlighting the versatility of this technique and potentially enabling the monitoring of wildlife as well as human populations with this assay. We were thus able to develop and validate a sensitive and broadly reactive high-throughput serological assay which could be used as a screening tool to detect antibodies against several highly pathogenic viruses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Diseases / Immunoassay / Nucleocapsid Proteins / Microspheres / Antibodies, Viral Type of study: Diagnostic study / Prognostic study Limits: Animals / Humans Language: English Journal: PLoS Negl Trop Dis Journal subject: Tropical Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pntd.0008699

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Diseases / Immunoassay / Nucleocapsid Proteins / Microspheres / Antibodies, Viral Type of study: Diagnostic study / Prognostic study Limits: Animals / Humans Language: English Journal: PLoS Negl Trop Dis Journal subject: Tropical Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pntd.0008699